Open AccessS188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY‐BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS
Author(s) -
Rodriguez Otero P.,
D'Souza A.,
Reece D.,
Donk N. W.,
Chari A.,
Krishnan A.,
Martin T.,
Mateos M. V.,
Morillo D.,
Hurd D.,
Rosinol L.,
Balari A. S.,
Wäsch R.,
Vishwamitra D.,
Wang Lin S. X.,
Prior T.,
Vandenberk L.,
Smit M.A. D.,
Oriol A.,
Dholaria B.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843644.02496.66
Subject(s) - daratumumab , medicine , oncology , multiple myeloma , adverse effect , phases of clinical research , refractory (planetary science) , clinical trial , bortezomib , astrobiology , physics